Following the success of the sell-out Cell Based Assay series, we are delighted to launch its inaugural conference on
3D Cell Culture which takes place on the 22nd and 23rd of February 2017 in London.
With a focus on clinical successes and emerging technologies, the conference will showcase how
3D Cell Culture has revolutionized drug discovery and toxicity screening, as well as how it is emerging as an invaluable tool in stem cell research and regenerative medicine. The event will also highlight exciting opportunities and latest innovations, spheroid and organoid techniques, as well as key developments in 3D and 4D bio-printing, microfluidics, CRISPR and the ongoing debate of 2D vs
3D cell culuture.
Highlights Include:
- Compare the benefits and potential of 3D Cell Culture over 2D Cell Culture with Stefan Przyborski, Professor of Cell Technology, Durham University
- Sanofi Aventis will be giving a technology update and comparisons of the latest technology available to 3D Cell Culture
- Gain insights into high throughtput screening, and the use of CRISPR in 3D cultures from Novartis
- Hear GlaxoSmithKline's take on the use of 3D Cell Culture in toxicity investigations
- Explore successful case studies on drug discovery and target validation with AstraZeneca
- Discover how to harness organoid technology for personalised models of drug discovery with Hubrecht Organoid Technology Foundation
- Discuss the EU regulatory considerations for use of cells in drug manufacturing with MHRA
Plus An Interactive Half-Day Pre-Conference Workshop | Tuesday 21st February 2017
Bio-printingLeader: William Whitford, Strategic Solutions Leader, GE Healthcare Life Sciences
08.30am - 13.00pm
Speakers
- Benedicte Gagny, Specialiste Application Culture Cellulaire Et Biologie, Sigma Aldrich
- Carlo Cusulin, Postdoctoral Researcher , Roche Diagnostics
- Christopher Dunsby, Senior Lecturer, Imperial College
- Christopher Schofield, Investigator, GSK
- Davide Danovi, Director, HipSci Cell Phenotyping, Centre for Stem Cells and Regenerative Medicine, King's College London,, King's College London
- Eytan Abraham, Head of Research & Technology for Emerging Technologies, Lonza Incorporated
- Louise Bisset, Biopharmaceutical Quality Assessor, MHRA
- Martin Guldenagel, Senior Techical Support Specialist, Corning, Inc
- Max Salick, Postdoctoral Researcher, Novartis Institutes For Biomedical Research
- Nils Goedecke, Founder, Microduits GmbH
- Olaf Galuba, Scientist, Novartis Pharmaceuticals
- Oliver Chao, Head, Emerging Biomedical Sciences, sanofi-aventis
- Peter Banks, Scientific Director, Biotek Inc
- Radek Polanski, Senior Research Scientist , AstraZeneca
- Reyk Horland, Head of Business Development, Tissuse G Mb H
- Robert Vries, Managing Director, Hubrecht Institute
- Samuel Constant, COO, Epithelix
- Stefan Przyborski, Founder and CSO, Durham University
- Ute Vespermann, Drug Discovery Specialist, Corning
- William Whitford, Strategic Solutions Leader, GE Healthcare
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under donwloads at the right side of the page.
Venue
Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK
Who should attend?
Directors, Supervisors, Specialists, Principal Scientists, Product Managers, Science Officer, Chief Scientific Officer, CEO, COO, Project Manager, Lead Scientists, Senior Scientists, Project leaders, Labheads, Research Scientists, Engineers, Senior Pharmacologists, Professors in the following areas:
- Cell culture
- Stem cell and regenerative medicine
- Process development - early and late stage
- Large scale manufacturing
- Cell therapy
- Cell technology
- High Throughput Screening
- Assay development and screening
- Business development
Venue
Copthorne Tara HotelScarsdale Place
Kensington
London, United Kingdom
